Tailoring access to high cost, genetically targeted drugs

Med J Aust. 2005 Jun 20;182(12):607-8. doi: 10.5694/j.1326-5377.2005.tb06844.x.

Abstract

Assessment of real cost effectiveness, with data linked to individual health outcomes while protecting patient privacy, is an essential challenge we need to meet.

Publication types

  • Editorial

MeSH terms

  • Advisory Committees
  • Australia
  • Confidentiality
  • Cost-Benefit Analysis
  • Decision Making, Organizational
  • Drug Approval
  • Drug Costs*
  • Financing, Government*
  • Health Services Accessibility / economics*
  • Humans
  • Insurance, Pharmaceutical Services / economics*
  • Pharmacogenetics*